愿你好运来 personal page - To The Moon

愿你好运来

愿你好运来

No personal profile

113Follow

2Followers

0Topic

0Badge

愿你好运来

2021-07-03

Good

Sorry, the original content has been removed

愿你好运来

2021-06-25

good

Didi updates its prospectus, pricing the IPO at $13.50.

愿你好运来

2021-06-25

y

Sorry, the original content has been removed

愿你好运来

2021-06-24

Good

Chaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.

愿你好运来

2021-06-24

yes

Dingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585419737505851","uuid":"3585419737505851","gmtCreate":1624064668127,"gmtModify":1624154013223,"name":"愿你好运来","pinyin":"ynhylyuannihaoyunlai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":113,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.18","exceedPercentage":"80.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.11","exceedPercentage":"80.83%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":152924650,"gmtCreate":1625264928470,"gmtModify":1703739500609,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152924650","repostId":"2148879648","repostType":4,"isVote":1,"tweetType":1,"viewCount":4442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126457214,"gmtCreate":1624582717038,"gmtModify":1703840862963,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126457214","repostId":"1190242896","repostType":4,"repost":{"id":"1190242896","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624571770,"share":"https://ttm.financial/m/news/1190242896?lang=en_US&edition=fundamental","pubTime":"2021-06-25 05:56","market":"hk","language":"zh","title":"Didi updates its prospectus, pricing the IPO at $13.50.","url":"https://stock-news.laohu8.com/highlight/detail?id=1190242896","media":"老虎资讯综合","summary":"北京时间6月25日凌晨消息，滴滴今日更新招股书，预计将把美国IPO定价设在定价区间的中部13.5美元/ADS，计划通过美国IPO发行2.88亿份ADS，代表7200万股A类普通股。\n北京时间6月11日","content":"<p>Early morning of June 25th, Beijing time, Didi updated its prospectus today, expecting to price its US IPO at $13.50 per ADS in the middle of the pricing range. It plans to issue 288 million ADS through the US IPO, representing 72 million Class A common shares.</p><p>On June 11, Beijing time, DIDI Chuxing officially filed for an IPO with the U.S. Securities and Exchange Commission (SEC), intending to list on the New York Stock Exchange under the ticker symbol \"DIDI.\" Goldman Sachs, Morgan Stanley, JPMorgan Chase, and China Renaissance Capital served as underwriters.</p><p>According to the prospectus, in the 12 months ending March 31, 2021, Didi had 493 million annual active users and 15 million annual active drivers worldwide. From March 31, 2020 to March 31, 2021, Didi had 377 million annual active users and 13 million annual active drivers in China. In the first quarter of 2021, Didi China Mobility had 156 million monthly active users and an average daily transaction volume of 25 million rides in China.</p><p>As of March 2021, Didi operated in more than 4,000 towns in 15 countries, including China, providing services such as ride-hailing, taxis, ride-sharing, bike-sharing, electric bike-sharing, chauffeur service, car service, freight, finance, and autonomous driving.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Didi updates its prospectus, pricing the IPO at $13.50.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDidi updates its prospectus, pricing the IPO at $13.50.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-25 05:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Early morning of June 25th, Beijing time, Didi updated its prospectus today, expecting to price its US IPO at $13.50 per ADS in the middle of the pricing range. It plans to issue 288 million ADS through the US IPO, representing 72 million Class A common shares.</p><p>On June 11, Beijing time, DIDI Chuxing officially filed for an IPO with the U.S. Securities and Exchange Commission (SEC), intending to list on the New York Stock Exchange under the ticker symbol \"DIDI.\" Goldman Sachs, Morgan Stanley, JPMorgan Chase, and China Renaissance Capital served as underwriters.</p><p>According to the prospectus, in the 12 months ending March 31, 2021, Didi had 493 million annual active users and 15 million annual active drivers worldwide. From March 31, 2020 to March 31, 2021, Didi had 377 million annual active users and 13 million annual active drivers in China. In the first quarter of 2021, Didi China Mobility had 156 million monthly active users and an average daily transaction volume of 25 million rides in China.</p><p>As of March 2021, Didi operated in more than 4,000 towns in 15 countries, including China, providing services such as ride-hailing, taxis, ride-sharing, bike-sharing, electric bike-sharing, chauffeur service, car service, freight, finance, and autonomous driving.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bf210b0a9da00c82cb2c925171714e26","relate_stocks":{"DIDI":"滴滴(已退市)"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190242896","content_text":"北京时间6月25日凌晨消息，滴滴今日更新招股书，预计将把美国IPO定价设在定价区间的中部13.5美元/ADS，计划通过美国IPO发行2.88亿份ADS，代表7200万股A类普通股。\n北京时间6月11日，滴滴出行正式向美国证券交易委员会（SEC）递交IPO申请，拟于纽交所挂牌上市，股票代码为“DIDI“。高盛、摩根士丹利、摩根大通、华兴资本担任承销商。\n招股书显示，在截至2021年3月31日的12个月里，滴滴全球年活跃用户为4.93亿，全球年活跃司机1500万。其中，自2020年3月31日至2021年3月31日，滴滴在中国拥有3.77亿年活跃用户和1300万年活跃司机。2021年第一季度，滴滴中国出行拥有1.56亿月活用户，中国出行业务日均交易量为2500万次。\n截至2021年3月，滴滴在包括中国在内的15个国家约4000多个城镇开展业务，提供网约车、出租车、顺风车、共享单车、共享电单车、代驾、车服、货运、金融和自动驾驶等服务。","news_type":1,"symbols_score_info":{"DIDI":0.9}},"isVote":1,"tweetType":1,"viewCount":4101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126458403,"gmtCreate":1624582559302,"gmtModify":1703840856138,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"y","listText":"y","text":"y","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126458403","repostId":"1183560687","repostType":4,"isVote":1,"tweetType":1,"viewCount":3804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128327226,"gmtCreate":1624502793165,"gmtModify":1703838583406,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128327226","repostId":"1136951406","repostType":4,"repost":{"id":"1136951406","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624497362,"share":"https://ttm.financial/m/news/1136951406?lang=en_US&edition=fundamental","pubTime":"2021-06-24 09:16","market":"hk","language":"zh","title":"Chaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.","url":"https://stock-news.laohu8.com/highlight/detail?id=1136951406","media":"老虎资讯综合","summary":"6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元","content":"<p>On June 24, Chaoju Eye Hospital issued an announcement stating that the company will conduct its IPO from June 24 to June 29; The company plans to offer 170.93 million shares globally, including 17.093 million shares offered in Hong Kong and 153.837 million shares offered internationally; The issue price per share is HK$9.48-10.60, with trading units of 500 shares per lot, and the entry fee is approximately HK$5,353.41; Haitong International and Huatai International are the joint sponsors, and the Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/396a841474a75b2709096e6774872273\" tg-width=\"850\" tg-height=\"763\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot consists of 500 shares, with an entry fee of HK$5,353.41.</p><p>The threshold for Group B is 500,000 shares, and the funds required for subscription are approximately HK$5,353,408.1.</p><p><img src=\"https://static.tigerbbs.com/3ad211e1911379810ca70b4c49d2cfe8\" tg-width=\"1153\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading ophthalmic medical service group in North China and a nationally renowned company. According to the Frost & Sullivan Report, among private eye hospitals, the Group ranked first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020. China has a large and rapidly growing market for ophthalmic medical services. According to the Frost & Sullivan Report, the size of China's ophthalmic medical services market increased from RMB73 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further increase to RMB223.1 billion in 2024; The size of the ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion in 2024; The size of the ophthalmic medical services market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With the increasing population and the strong demand for ophthalmic medical services, the growth potential of the ophthalmic medical services market in China is expected to be huge. Leveraging on the Group's experience and market leadership in ophthalmic services, the Group believes that the Group is well positioned to capture the growing opportunities and benefit from the rapid expansion of the ophthalmic services market in the PRC.</p><p>During the Track Record Period, the Group experienced rapid growth. The Group's revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. The Group's net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. In 2018, 2019 and 2020, the number of patient visits at the Group's hospitals was 638,650, 702,143 and 696,206, respectively, and the number of customer visits at the Optometry Centre was 73,935, 79,903 and 91,660, respectively.</p><p><img src=\"https://static.tigerbbs.com/9b85516f9bf7cbda5d3618c2a26e58d7\" tg-width=\"957\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p>The Group has entered into a cornerstone investment agreement with the Cornerstone Investor, pursuant to which the Cornerstone Investor has agreed to subscribe for, or procure its designated entities to subscribe for, a certain number of Offer Shares at the Offer Price. The Cornerstone Investors have agreed to subscribe for such number of Offer Shares at the Offer Price, totalling US$102 million or approximately HK$792 million. Based on the offer price of HK$10.04 per share (i.e., the mid-point of the offer price range), and assuming the over-allotment option is not exercised, the total number of shares to be subscribed by cornerstone investors is 78.8395 million, representing approximately 46.12% of the offer shares and approximately 11.47% of the total issued share capital immediately following the completion of the global offering. Cornerstone investors include Wells Fargo Fund Management Limited, Gigantic Wealth Holdings Limited, Tongbai Capital (Hong Kong) Limited, and The Valliance Fund.</p><p><img src=\"https://static.tigerbbs.com/bec0f4980a5f1eb938ada0e1abe84825\" tg-width=\"946\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>Assuming an offer price of HK$10.04 per share (i.e., the mid-point of the offer price range) and assuming the over-allotment option is not exercised, the Group estimates that the net proceeds from the global offering will be approximately HK$1.2832 billion. Among them, approximately 35.8% of the net proceeds from the Global Offering will be used for the construction of new hospitals and the relocation, upgrading and renovation of existing hospitals; Approximately 44.8% will be used to acquire hospitals in new markets with large populations and relatively high demand for ophthalmic medical services when suitable opportunities arise; Approximately 9.4% will be used to upgrade the Group's information technology systems; and approximately 10.0% will be used for working capital and other general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-24 09:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 24, Chaoju Eye Hospital issued an announcement stating that the company will conduct its IPO from June 24 to June 29; The company plans to offer 170.93 million shares globally, including 17.093 million shares offered in Hong Kong and 153.837 million shares offered internationally; The issue price per share is HK$9.48-10.60, with trading units of 500 shares per lot, and the entry fee is approximately HK$5,353.41; Haitong International and Huatai International are the joint sponsors, and the Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/396a841474a75b2709096e6774872273\" tg-width=\"850\" tg-height=\"763\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot consists of 500 shares, with an entry fee of HK$5,353.41.</p><p>The threshold for Group B is 500,000 shares, and the funds required for subscription are approximately HK$5,353,408.1.</p><p><img src=\"https://static.tigerbbs.com/3ad211e1911379810ca70b4c49d2cfe8\" tg-width=\"1153\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading ophthalmic medical service group in North China and a nationally renowned company. According to the Frost & Sullivan Report, among private eye hospitals, the Group ranked first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020. China has a large and rapidly growing market for ophthalmic medical services. According to the Frost & Sullivan Report, the size of China's ophthalmic medical services market increased from RMB73 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further increase to RMB223.1 billion in 2024; The size of the ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion in 2024; The size of the ophthalmic medical services market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With the increasing population and the strong demand for ophthalmic medical services, the growth potential of the ophthalmic medical services market in China is expected to be huge. Leveraging on the Group's experience and market leadership in ophthalmic services, the Group believes that the Group is well positioned to capture the growing opportunities and benefit from the rapid expansion of the ophthalmic services market in the PRC.</p><p>During the Track Record Period, the Group experienced rapid growth. The Group's revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. The Group's net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. In 2018, 2019 and 2020, the number of patient visits at the Group's hospitals was 638,650, 702,143 and 696,206, respectively, and the number of customer visits at the Optometry Centre was 73,935, 79,903 and 91,660, respectively.</p><p><img src=\"https://static.tigerbbs.com/9b85516f9bf7cbda5d3618c2a26e58d7\" tg-width=\"957\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p>The Group has entered into a cornerstone investment agreement with the Cornerstone Investor, pursuant to which the Cornerstone Investor has agreed to subscribe for, or procure its designated entities to subscribe for, a certain number of Offer Shares at the Offer Price. The Cornerstone Investors have agreed to subscribe for such number of Offer Shares at the Offer Price, totalling US$102 million or approximately HK$792 million. Based on the offer price of HK$10.04 per share (i.e., the mid-point of the offer price range), and assuming the over-allotment option is not exercised, the total number of shares to be subscribed by cornerstone investors is 78.8395 million, representing approximately 46.12% of the offer shares and approximately 11.47% of the total issued share capital immediately following the completion of the global offering. Cornerstone investors include Wells Fargo Fund Management Limited, Gigantic Wealth Holdings Limited, Tongbai Capital (Hong Kong) Limited, and The Valliance Fund.</p><p><img src=\"https://static.tigerbbs.com/bec0f4980a5f1eb938ada0e1abe84825\" tg-width=\"946\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>Assuming an offer price of HK$10.04 per share (i.e., the mid-point of the offer price range) and assuming the over-allotment option is not exercised, the Group estimates that the net proceeds from the global offering will be approximately HK$1.2832 billion. Among them, approximately 35.8% of the net proceeds from the Global Offering will be used for the construction of new hospitals and the relocation, upgrading and renovation of existing hospitals; Approximately 44.8% will be used to acquire hospitals in new markets with large populations and relatively high demand for ophthalmic medical services when suitable opportunities arise; Approximately 9.4% will be used to upgrade the Group's information technology systems; and approximately 10.0% will be used for working capital and other general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"02219":"朝聚眼科"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136951406","content_text":"6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元，每手买卖单位500股，入场费约5353.41港元；海通国际及华泰国际为联席保荐人，预期股份将于7月7日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手500股，入场费5353.41港元。\n乙组门槛为50万股，申购所需资金约5353408.1港元。\n\n集团是中国华北地区领先、全国知名的眼科医疗服务集团。根据弗若斯特沙利文报告，于民营眼科医院中，按2020年的收益总额计，集团在内蒙古排名第一、在中国华北地区排名第二及在中国排名第五。中国拥有一个庞大且快速成长的眼科医疗服务市场。根据弗若斯特沙利文报告，中国眼科医疗服务市场的规模从2015年的人民币730亿元增加至2019年的人民币1,275亿元，复合年增长率达15.0%，预计将进一步增至2024年的人民币2,231亿元；中国华北地区眼科医疗服务市场的规模从2015年的人民币132亿元增加至2019年的人民币212亿元，复合年增长率达12.5%，预计将进一步增长至2024年的人民币337亿元；内蒙古眼科医疗服务市场的规模由2015年的人民币11亿元增至2019年的人民币20亿元，复合年增长率达15.6%，预期将进一步增长至2024年的人民币33亿元。随着人口增加，加上眼科医疗服务需求殷切，预期中国眼科医疗服务市场的增长潜力庞大。凭藉集团于眼科服务的经验及市场领先优势，集团相信集团处于有利位置以把握不断增长的机遇，并从中国眼科服务市场的快速扩展中受惠。\n于往绩记录期间，集团迎来快速增长。集团的收益由2018年的人民币6.327亿元增加13.0%至2019年的人民币7.147亿元，并进一步增加11.1%至2020年的人民币7.943亿元。集团的纯利亦由2018年的人民币2920万元大幅增加至2019年的人民币7080万元，并进一步增加70.2%至2020年的人民币1.205亿元。于2018年、2019年及2020年，集团医院的患者就诊人次分别为638,650名、702,143名及696,206名，且视光中心的客户就诊人次分别为73,935名、79,903名及91,660名。\n\n集团已与基石投资者订立基石投资协议，据此，基石投资者已同意按发售价认购或促使其指定实体按发售价认购若干数目的发售股份。基石投资者已同意按发售价认购可认购有关数目的发售股份，总额为1.02亿美元或约7.92亿港元。按发售价每股10.04港元(即发售价范围中位数)计算，假设超额配股权不获行使，基石投资者将予认购的股份总数为7883.95万股，占发售股份约46.12%及紧随全球发售完成后已发行股本总额约11.47%。基石投资者包括富国基金管理有限公司、Gigantic Wealth Holdings Limited、通柏资本(香港)有限公司、及The Valliance Fund。\n\n假设发售价为每股10.04港元(即发售价范围中位数)，并假设超额配股权未获行使，集团估计收取的全球发售所得款项净额将约为12.832亿港元。其中，全球发售所得款项净额约35.8%将用于建立新医院以及搬迁、升级及装修现有医院；约44.8%将在出现合适机遇时，用于在人口庞大且对眼科医疗服务需求相对较高的新市场中收购医院；约9.4%将用于升级集团的信息技术系统；及约10.0%将用于营运资金及其他一般企业用途。","news_type":1,"symbols_score_info":{"02219":0.9}},"isVote":1,"tweetType":1,"viewCount":4293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121544150,"gmtCreate":1624485414570,"gmtModify":1703837902164,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121544150","repostId":"1158050536","repostType":4,"repost":{"id":"1158050536","kind":"news","pubTimestamp":1624458764,"share":"https://ttm.financial/m/news/1158050536?lang=en_US&edition=fundamental","pubTime":"2021-06-23 22:32","market":"hk","language":"zh","title":"Dingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.","url":"https://stock-news.laohu8.com/highlight/detail?id=1158050536","media":"新浪科技","summary":"中金与招银国际为联席保荐人。","content":"<p>On the evening of June 23, Dingdang Health Technology Group Co., Ltd., the subsidiary of the internet health delivery service platform \"Dingdang Express Medicine\", submitted a listing application to the Hong Kong Stock Exchange, with CICC and CMB International as joint sponsors.</p><p>According to the prospectus, Dingdang Express Pharmaceutical's revenue was RMB 584.6 million, RMB 1.276 billion, and RMB 2.229 billion in 2018, 2018, and 2020, respectively. For the three months ended March 31, 2021, Dingdang Express's revenue was RMB 780 million. The company achieved a compound annual growth rate of 95.2% from 2018 to 2020.</p><p>In terms of revenue structure, Dingdang Express Pharmaceutical's revenue is mainly contributed by pharmaceutical and medical businesses, accounting for more than 95% of both. During the reporting period, revenue from pharmaceutical and medical services was RMB 562 million, RMB 1.251 billion, RMB 2.204 billion and RMB 761 million, respectively, accounting for 96.2%, 98.1%, 98.9% and 97.6%.</p><p>Dingdang Express Pharmaceutical suffered net losses of RMB 103 million, RMB 274 million, and RMB 920 million in 2018, 2018, and 2020, respectively, with adjusted net losses of RMB 69.552 million, RMB 123 million, and RMB 149 million, respectively. The company reported a net loss of 764 million yuan in the first quarter of 2021, compared to an adjusted net loss of 88.212 million yuan.</p><p><img src=\"https://static.tigerbbs.com/84671b41e90e8ab7fb7df16b5269a9e7\" tg-width=\"550\" tg-height=\"334\" referrerpolicy=\"no-referrer\"></p><p>In terms of cash flow, as of March 31, 2021, Dingdang Express Pharmaceutical's cash and cash equivalents at the end of the year or period were RMB 427 million.</p><p>The prospectus also shows that the company's express drug service supply recorded a total of 141 million, 264 million, and 405 million sales orders from 2018 to 2020, respectively. During the same period, the platform's online doctor consultation service recorded a total of 100,000, 2.2 million, and 4.4 million online consultations, respectively. For the three months ended March 31, 2021, Dingdang Express recorded 129 million sales orders for its express medicine service and 1.3 million online consultations for its online doctor consultation service.</p><p>In terms of equity, Yang Wenlong, founder of Dingdang Health and Dingdang Express Pharmaceutical, holds a total of 53.23% of the shares, CMB International holds a total of 7.28%, TPG Capital holds 6.34%, SoftBank holds a total of 5.96%, and Taikang Life Insurance holds 2.06%.<a href=\"https://laohu8.com/S/601995\">CICC</a>OrbiMed holds 1.97% of the shares, OrbiMed Capital holds 1.27%, and a fund under Haier Group holds 1.03%.</p><p><img src=\"https://static.tigerbbs.com/b90772c12a9057c339d9c403a112fb15\" tg-width=\"550\" tg-height=\"455\" referrerpolicy=\"no-referrer\"></p>","source":"sina_tech","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪科技</strong><span class=\"h-time small\">2021-06-23 22:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>On the evening of June 23, Dingdang Health Technology Group Co., Ltd., the subsidiary of the internet health delivery service platform \"Dingdang Express Medicine\", submitted a listing application to the Hong Kong Stock Exchange, with CICC and CMB International as joint sponsors.</p><p>According to the prospectus, Dingdang Express Pharmaceutical's revenue was RMB 584.6 million, RMB 1.276 billion, and RMB 2.229 billion in 2018, 2018, and 2020, respectively. For the three months ended March 31, 2021, Dingdang Express's revenue was RMB 780 million. The company achieved a compound annual growth rate of 95.2% from 2018 to 2020.</p><p>In terms of revenue structure, Dingdang Express Pharmaceutical's revenue is mainly contributed by pharmaceutical and medical businesses, accounting for more than 95% of both. During the reporting period, revenue from pharmaceutical and medical services was RMB 562 million, RMB 1.251 billion, RMB 2.204 billion and RMB 761 million, respectively, accounting for 96.2%, 98.1%, 98.9% and 97.6%.</p><p>Dingdang Express Pharmaceutical suffered net losses of RMB 103 million, RMB 274 million, and RMB 920 million in 2018, 2018, and 2020, respectively, with adjusted net losses of RMB 69.552 million, RMB 123 million, and RMB 149 million, respectively. The company reported a net loss of 764 million yuan in the first quarter of 2021, compared to an adjusted net loss of 88.212 million yuan.</p><p><img src=\"https://static.tigerbbs.com/84671b41e90e8ab7fb7df16b5269a9e7\" tg-width=\"550\" tg-height=\"334\" referrerpolicy=\"no-referrer\"></p><p>In terms of cash flow, as of March 31, 2021, Dingdang Express Pharmaceutical's cash and cash equivalents at the end of the year or period were RMB 427 million.</p><p>The prospectus also shows that the company's express drug service supply recorded a total of 141 million, 264 million, and 405 million sales orders from 2018 to 2020, respectively. During the same period, the platform's online doctor consultation service recorded a total of 100,000, 2.2 million, and 4.4 million online consultations, respectively. For the three months ended March 31, 2021, Dingdang Express recorded 129 million sales orders for its express medicine service and 1.3 million online consultations for its online doctor consultation service.</p><p>In terms of equity, Yang Wenlong, founder of Dingdang Health and Dingdang Express Pharmaceutical, holds a total of 53.23% of the shares, CMB International holds a total of 7.28%, TPG Capital holds 6.34%, SoftBank holds a total of 5.96%, and Taikang Life Insurance holds 2.06%.<a href=\"https://laohu8.com/S/601995\">CICC</a>OrbiMed holds 1.97% of the shares, OrbiMed Capital holds 1.27%, and a fund under Haier Group holds 1.03%.</p><p><img src=\"https://static.tigerbbs.com/b90772c12a9057c339d9c403a112fb15\" tg-width=\"550\" tg-height=\"455\" referrerpolicy=\"no-referrer\"></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/tech/2021-06-23/doc-ikqciyzk1422330.shtml\">新浪科技</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4e0b225f7e22da3febd11eab17f77d01","relate_stocks":{"HSI":"恒生指数"},"source_url":"https://finance.sina.com.cn/tech/2021-06-23/doc-ikqciyzk1422330.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158050536","content_text":"6月23日晚间消息，互联网健康到家服务平台“叮当快药”所属公司叮当健康科技集团有限公司向港交所递交上市申请，中金与招银国际为联席保荐人。\n招股书显示，叮当快药2018年-2020年的收入分别为5.846亿元，12.76亿元，22.29亿。截至2021年3月31日止三个月，叮当快药收入为7.80亿元。该公司2018年至2020年复合增长率为95.2%。\n按收入结构来看，叮当快药的收入主要由药品及医疗业务贡献，占比均超过95%。报告期内，药品及医疗业务收入分别为5.62亿元、12.51亿元、22.04亿元与7.61亿元，占比分别为96.2%、98.1%、98.9%与97.6%。\n叮当快药2018年-2020年净亏损分别为达1.03亿元，2.74亿元，9.20亿元，经调整后的净亏损分别为6955.2万元、1.23亿元、1.49亿元。该公司2021年第一季度净亏损为7.64亿元，经调整净亏损为8821.2万元。\n\n在现金流方面，截止2021年3月31日，叮当快药的年或期末现金及现金等价物为4.27亿元。\n招股书还显示，该公司快药服务供应2018年至2020年，分别录得合共1.41亿笔、2.64亿笔、4.05亿笔销售订单，同期的平台在线医生诊疗服务分别录得共10万、220万、440万次在线咨询。截至2021年3月31日止三个月，叮当快药的快药服务供应录得1.29亿笔销售订单，平台在线医生诊疗服务录得130万次在线咨询。\n股权方面来看，叮当健康、叮当快药创始人杨文龙合计持有53.23%股权，招银国际合计持股7.28%，TPG Capital持股6.34%，软银合计持股5.96%，泰康人寿保险持股2.06%，中金公司持股1.97%，OrbiMed奥博资本持股1.27%，海尔集团旗下基金持股1.03%。","news_type":1,"symbols_score_info":{"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":4696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":152924650,"gmtCreate":1625264928470,"gmtModify":1703739500609,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152924650","repostId":"2148879648","repostType":4,"isVote":1,"tweetType":1,"viewCount":4442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128327226,"gmtCreate":1624502793165,"gmtModify":1703838583406,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128327226","repostId":"1136951406","repostType":4,"repost":{"id":"1136951406","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624497362,"share":"https://ttm.financial/m/news/1136951406?lang=en_US&edition=fundamental","pubTime":"2021-06-24 09:16","market":"hk","language":"zh","title":"Chaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.","url":"https://stock-news.laohu8.com/highlight/detail?id=1136951406","media":"老虎资讯综合","summary":"6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元","content":"<p>On June 24, Chaoju Eye Hospital issued an announcement stating that the company will conduct its IPO from June 24 to June 29; The company plans to offer 170.93 million shares globally, including 17.093 million shares offered in Hong Kong and 153.837 million shares offered internationally; The issue price per share is HK$9.48-10.60, with trading units of 500 shares per lot, and the entry fee is approximately HK$5,353.41; Haitong International and Huatai International are the joint sponsors, and the Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/396a841474a75b2709096e6774872273\" tg-width=\"850\" tg-height=\"763\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot consists of 500 shares, with an entry fee of HK$5,353.41.</p><p>The threshold for Group B is 500,000 shares, and the funds required for subscription are approximately HK$5,353,408.1.</p><p><img src=\"https://static.tigerbbs.com/3ad211e1911379810ca70b4c49d2cfe8\" tg-width=\"1153\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading ophthalmic medical service group in North China and a nationally renowned company. According to the Frost & Sullivan Report, among private eye hospitals, the Group ranked first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020. China has a large and rapidly growing market for ophthalmic medical services. According to the Frost & Sullivan Report, the size of China's ophthalmic medical services market increased from RMB73 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further increase to RMB223.1 billion in 2024; The size of the ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion in 2024; The size of the ophthalmic medical services market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With the increasing population and the strong demand for ophthalmic medical services, the growth potential of the ophthalmic medical services market in China is expected to be huge. Leveraging on the Group's experience and market leadership in ophthalmic services, the Group believes that the Group is well positioned to capture the growing opportunities and benefit from the rapid expansion of the ophthalmic services market in the PRC.</p><p>During the Track Record Period, the Group experienced rapid growth. The Group's revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. The Group's net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. In 2018, 2019 and 2020, the number of patient visits at the Group's hospitals was 638,650, 702,143 and 696,206, respectively, and the number of customer visits at the Optometry Centre was 73,935, 79,903 and 91,660, respectively.</p><p><img src=\"https://static.tigerbbs.com/9b85516f9bf7cbda5d3618c2a26e58d7\" tg-width=\"957\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p>The Group has entered into a cornerstone investment agreement with the Cornerstone Investor, pursuant to which the Cornerstone Investor has agreed to subscribe for, or procure its designated entities to subscribe for, a certain number of Offer Shares at the Offer Price. The Cornerstone Investors have agreed to subscribe for such number of Offer Shares at the Offer Price, totalling US$102 million or approximately HK$792 million. Based on the offer price of HK$10.04 per share (i.e., the mid-point of the offer price range), and assuming the over-allotment option is not exercised, the total number of shares to be subscribed by cornerstone investors is 78.8395 million, representing approximately 46.12% of the offer shares and approximately 11.47% of the total issued share capital immediately following the completion of the global offering. Cornerstone investors include Wells Fargo Fund Management Limited, Gigantic Wealth Holdings Limited, Tongbai Capital (Hong Kong) Limited, and The Valliance Fund.</p><p><img src=\"https://static.tigerbbs.com/bec0f4980a5f1eb938ada0e1abe84825\" tg-width=\"946\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>Assuming an offer price of HK$10.04 per share (i.e., the mid-point of the offer price range) and assuming the over-allotment option is not exercised, the Group estimates that the net proceeds from the global offering will be approximately HK$1.2832 billion. Among them, approximately 35.8% of the net proceeds from the Global Offering will be used for the construction of new hospitals and the relocation, upgrading and renovation of existing hospitals; Approximately 44.8% will be used to acquire hospitals in new markets with large populations and relatively high demand for ophthalmic medical services when suitable opportunities arise; Approximately 9.4% will be used to upgrade the Group's information technology systems; and approximately 10.0% will be used for working capital and other general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChaoju Eye Hospital launches its IPO today, with an entry fee of approximately HK$5,353.41 per lot.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-24 09:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On June 24, Chaoju Eye Hospital issued an announcement stating that the company will conduct its IPO from June 24 to June 29; The company plans to offer 170.93 million shares globally, including 17.093 million shares offered in Hong Kong and 153.837 million shares offered internationally; The issue price per share is HK$9.48-10.60, with trading units of 500 shares per lot, and the entry fee is approximately HK$5,353.41; Haitong International and Huatai International are the joint sponsors, and the Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30.</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription portal</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/396a841474a75b2709096e6774872273\" tg-width=\"850\" tg-height=\"763\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Each lot consists of 500 shares, with an entry fee of HK$5,353.41.</p><p>The threshold for Group B is 500,000 shares, and the funds required for subscription are approximately HK$5,353,408.1.</p><p><img src=\"https://static.tigerbbs.com/3ad211e1911379810ca70b4c49d2cfe8\" tg-width=\"1153\" tg-height=\"662\" referrerpolicy=\"no-referrer\"></p><p>The Group is a leading ophthalmic medical service group in North China and a nationally renowned company. According to the Frost & Sullivan Report, among private eye hospitals, the Group ranked first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020. China has a large and rapidly growing market for ophthalmic medical services. According to the Frost & Sullivan Report, the size of China's ophthalmic medical services market increased from RMB73 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further increase to RMB223.1 billion in 2024; The size of the ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion in 2024; The size of the ophthalmic medical services market in Inner Mongolia increased from RMB1.1 billion in 2015 to RMB2 billion in 2019, representing a CAGR of 15.6%, and is expected to further grow to RMB3.3 billion in 2024. With the increasing population and the strong demand for ophthalmic medical services, the growth potential of the ophthalmic medical services market in China is expected to be huge. Leveraging on the Group's experience and market leadership in ophthalmic services, the Group believes that the Group is well positioned to capture the growing opportunities and benefit from the rapid expansion of the ophthalmic services market in the PRC.</p><p>During the Track Record Period, the Group experienced rapid growth. The Group's revenue increased by 13.0% from RMB632.7 million in 2018 to RMB714.7 million in 2019, and further increased by 11.1% to RMB794.3 million in 2020. The Group's net profit also increased significantly from RMB29.2 million in 2018 to RMB70.8 million in 2019, and further increased by 70.2% to RMB120.5 million in 2020. In 2018, 2019 and 2020, the number of patient visits at the Group's hospitals was 638,650, 702,143 and 696,206, respectively, and the number of customer visits at the Optometry Centre was 73,935, 79,903 and 91,660, respectively.</p><p><img src=\"https://static.tigerbbs.com/9b85516f9bf7cbda5d3618c2a26e58d7\" tg-width=\"957\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p>The Group has entered into a cornerstone investment agreement with the Cornerstone Investor, pursuant to which the Cornerstone Investor has agreed to subscribe for, or procure its designated entities to subscribe for, a certain number of Offer Shares at the Offer Price. The Cornerstone Investors have agreed to subscribe for such number of Offer Shares at the Offer Price, totalling US$102 million or approximately HK$792 million. Based on the offer price of HK$10.04 per share (i.e., the mid-point of the offer price range), and assuming the over-allotment option is not exercised, the total number of shares to be subscribed by cornerstone investors is 78.8395 million, representing approximately 46.12% of the offer shares and approximately 11.47% of the total issued share capital immediately following the completion of the global offering. Cornerstone investors include Wells Fargo Fund Management Limited, Gigantic Wealth Holdings Limited, Tongbai Capital (Hong Kong) Limited, and The Valliance Fund.</p><p><img src=\"https://static.tigerbbs.com/bec0f4980a5f1eb938ada0e1abe84825\" tg-width=\"946\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>Assuming an offer price of HK$10.04 per share (i.e., the mid-point of the offer price range) and assuming the over-allotment option is not exercised, the Group estimates that the net proceeds from the global offering will be approximately HK$1.2832 billion. Among them, approximately 35.8% of the net proceeds from the Global Offering will be used for the construction of new hospitals and the relocation, upgrading and renovation of existing hospitals; Approximately 44.8% will be used to acquire hospitals in new markets with large populations and relatively high demand for ophthalmic medical services when suitable opportunities arise; Approximately 9.4% will be used to upgrade the Group's information technology systems; and approximately 10.0% will be used for working capital and other general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"02219":"朝聚眼科"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136951406","content_text":"6月24日，朝聚眼科发布公告，公司于6月24日至6月29日招股；公司拟全球发售1.7093亿股股份，其中香港发售股份1709.3万股，国际发售股份1.53837亿股；每股发行价9.48-10.60港元，每手买卖单位500股，入场费约5353.41港元；海通国际及华泰国际为联席保荐人，预期股份将于7月7日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手500股，入场费5353.41港元。\n乙组门槛为50万股，申购所需资金约5353408.1港元。\n\n集团是中国华北地区领先、全国知名的眼科医疗服务集团。根据弗若斯特沙利文报告，于民营眼科医院中，按2020年的收益总额计，集团在内蒙古排名第一、在中国华北地区排名第二及在中国排名第五。中国拥有一个庞大且快速成长的眼科医疗服务市场。根据弗若斯特沙利文报告，中国眼科医疗服务市场的规模从2015年的人民币730亿元增加至2019年的人民币1,275亿元，复合年增长率达15.0%，预计将进一步增至2024年的人民币2,231亿元；中国华北地区眼科医疗服务市场的规模从2015年的人民币132亿元增加至2019年的人民币212亿元，复合年增长率达12.5%，预计将进一步增长至2024年的人民币337亿元；内蒙古眼科医疗服务市场的规模由2015年的人民币11亿元增至2019年的人民币20亿元，复合年增长率达15.6%，预期将进一步增长至2024年的人民币33亿元。随着人口增加，加上眼科医疗服务需求殷切，预期中国眼科医疗服务市场的增长潜力庞大。凭藉集团于眼科服务的经验及市场领先优势，集团相信集团处于有利位置以把握不断增长的机遇，并从中国眼科服务市场的快速扩展中受惠。\n于往绩记录期间，集团迎来快速增长。集团的收益由2018年的人民币6.327亿元增加13.0%至2019年的人民币7.147亿元，并进一步增加11.1%至2020年的人民币7.943亿元。集团的纯利亦由2018年的人民币2920万元大幅增加至2019年的人民币7080万元，并进一步增加70.2%至2020年的人民币1.205亿元。于2018年、2019年及2020年，集团医院的患者就诊人次分别为638,650名、702,143名及696,206名，且视光中心的客户就诊人次分别为73,935名、79,903名及91,660名。\n\n集团已与基石投资者订立基石投资协议，据此，基石投资者已同意按发售价认购或促使其指定实体按发售价认购若干数目的发售股份。基石投资者已同意按发售价认购可认购有关数目的发售股份，总额为1.02亿美元或约7.92亿港元。按发售价每股10.04港元(即发售价范围中位数)计算，假设超额配股权不获行使，基石投资者将予认购的股份总数为7883.95万股，占发售股份约46.12%及紧随全球发售完成后已发行股本总额约11.47%。基石投资者包括富国基金管理有限公司、Gigantic Wealth Holdings Limited、通柏资本(香港)有限公司、及The Valliance Fund。\n\n假设发售价为每股10.04港元(即发售价范围中位数)，并假设超额配股权未获行使，集团估计收取的全球发售所得款项净额将约为12.832亿港元。其中，全球发售所得款项净额约35.8%将用于建立新医院以及搬迁、升级及装修现有医院；约44.8%将在出现合适机遇时，用于在人口庞大且对眼科医疗服务需求相对较高的新市场中收购医院；约9.4%将用于升级集团的信息技术系统；及约10.0%将用于营运资金及其他一般企业用途。","news_type":1,"symbols_score_info":{"02219":0.9}},"isVote":1,"tweetType":1,"viewCount":4293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126458403,"gmtCreate":1624582559302,"gmtModify":1703840856138,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"y","listText":"y","text":"y","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126458403","repostId":"1183560687","repostType":4,"isVote":1,"tweetType":1,"viewCount":3804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126457214,"gmtCreate":1624582717038,"gmtModify":1703840862963,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126457214","repostId":"1190242896","repostType":4,"repost":{"id":"1190242896","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624571770,"share":"https://ttm.financial/m/news/1190242896?lang=en_US&edition=fundamental","pubTime":"2021-06-25 05:56","market":"hk","language":"zh","title":"Didi updates its prospectus, pricing the IPO at $13.50.","url":"https://stock-news.laohu8.com/highlight/detail?id=1190242896","media":"老虎资讯综合","summary":"北京时间6月25日凌晨消息，滴滴今日更新招股书，预计将把美国IPO定价设在定价区间的中部13.5美元/ADS，计划通过美国IPO发行2.88亿份ADS，代表7200万股A类普通股。\n北京时间6月11日","content":"<p>Early morning of June 25th, Beijing time, Didi updated its prospectus today, expecting to price its US IPO at $13.50 per ADS in the middle of the pricing range. It plans to issue 288 million ADS through the US IPO, representing 72 million Class A common shares.</p><p>On June 11, Beijing time, DIDI Chuxing officially filed for an IPO with the U.S. Securities and Exchange Commission (SEC), intending to list on the New York Stock Exchange under the ticker symbol \"DIDI.\" Goldman Sachs, Morgan Stanley, JPMorgan Chase, and China Renaissance Capital served as underwriters.</p><p>According to the prospectus, in the 12 months ending March 31, 2021, Didi had 493 million annual active users and 15 million annual active drivers worldwide. From March 31, 2020 to March 31, 2021, Didi had 377 million annual active users and 13 million annual active drivers in China. In the first quarter of 2021, Didi China Mobility had 156 million monthly active users and an average daily transaction volume of 25 million rides in China.</p><p>As of March 2021, Didi operated in more than 4,000 towns in 15 countries, including China, providing services such as ride-hailing, taxis, ride-sharing, bike-sharing, electric bike-sharing, chauffeur service, car service, freight, finance, and autonomous driving.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Didi updates its prospectus, pricing the IPO at $13.50.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDidi updates its prospectus, pricing the IPO at $13.50.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-25 05:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Early morning of June 25th, Beijing time, Didi updated its prospectus today, expecting to price its US IPO at $13.50 per ADS in the middle of the pricing range. It plans to issue 288 million ADS through the US IPO, representing 72 million Class A common shares.</p><p>On June 11, Beijing time, DIDI Chuxing officially filed for an IPO with the U.S. Securities and Exchange Commission (SEC), intending to list on the New York Stock Exchange under the ticker symbol \"DIDI.\" Goldman Sachs, Morgan Stanley, JPMorgan Chase, and China Renaissance Capital served as underwriters.</p><p>According to the prospectus, in the 12 months ending March 31, 2021, Didi had 493 million annual active users and 15 million annual active drivers worldwide. From March 31, 2020 to March 31, 2021, Didi had 377 million annual active users and 13 million annual active drivers in China. In the first quarter of 2021, Didi China Mobility had 156 million monthly active users and an average daily transaction volume of 25 million rides in China.</p><p>As of March 2021, Didi operated in more than 4,000 towns in 15 countries, including China, providing services such as ride-hailing, taxis, ride-sharing, bike-sharing, electric bike-sharing, chauffeur service, car service, freight, finance, and autonomous driving.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bf210b0a9da00c82cb2c925171714e26","relate_stocks":{"DIDI":"滴滴(已退市)"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190242896","content_text":"北京时间6月25日凌晨消息，滴滴今日更新招股书，预计将把美国IPO定价设在定价区间的中部13.5美元/ADS，计划通过美国IPO发行2.88亿份ADS，代表7200万股A类普通股。\n北京时间6月11日，滴滴出行正式向美国证券交易委员会（SEC）递交IPO申请，拟于纽交所挂牌上市，股票代码为“DIDI“。高盛、摩根士丹利、摩根大通、华兴资本担任承销商。\n招股书显示，在截至2021年3月31日的12个月里，滴滴全球年活跃用户为4.93亿，全球年活跃司机1500万。其中，自2020年3月31日至2021年3月31日，滴滴在中国拥有3.77亿年活跃用户和1300万年活跃司机。2021年第一季度，滴滴中国出行拥有1.56亿月活用户，中国出行业务日均交易量为2500万次。\n截至2021年3月，滴滴在包括中国在内的15个国家约4000多个城镇开展业务，提供网约车、出租车、顺风车、共享单车、共享电单车、代驾、车服、货运、金融和自动驾驶等服务。","news_type":1,"symbols_score_info":{"DIDI":0.9}},"isVote":1,"tweetType":1,"viewCount":4101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121544150,"gmtCreate":1624485414570,"gmtModify":1703837902164,"author":{"id":"3585419737505851","authorId":"3585419737505851","name":"愿你好运来","avatar":"https://static.tigerbbs.com/dff8294974b22aedabf774071aa3e6af","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585419737505851","idStr":"3585419737505851"},"themes":[],"title":"","htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121544150","repostId":"1158050536","repostType":4,"repost":{"id":"1158050536","kind":"news","pubTimestamp":1624458764,"share":"https://ttm.financial/m/news/1158050536?lang=en_US&edition=fundamental","pubTime":"2021-06-23 22:32","market":"hk","language":"zh","title":"Dingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.","url":"https://stock-news.laohu8.com/highlight/detail?id=1158050536","media":"新浪科技","summary":"中金与招银国际为联席保荐人。","content":"<p>On the evening of June 23, Dingdang Health Technology Group Co., Ltd., the subsidiary of the internet health delivery service platform \"Dingdang Express Medicine\", submitted a listing application to the Hong Kong Stock Exchange, with CICC and CMB International as joint sponsors.</p><p>According to the prospectus, Dingdang Express Pharmaceutical's revenue was RMB 584.6 million, RMB 1.276 billion, and RMB 2.229 billion in 2018, 2018, and 2020, respectively. For the three months ended March 31, 2021, Dingdang Express's revenue was RMB 780 million. The company achieved a compound annual growth rate of 95.2% from 2018 to 2020.</p><p>In terms of revenue structure, Dingdang Express Pharmaceutical's revenue is mainly contributed by pharmaceutical and medical businesses, accounting for more than 95% of both. During the reporting period, revenue from pharmaceutical and medical services was RMB 562 million, RMB 1.251 billion, RMB 2.204 billion and RMB 761 million, respectively, accounting for 96.2%, 98.1%, 98.9% and 97.6%.</p><p>Dingdang Express Pharmaceutical suffered net losses of RMB 103 million, RMB 274 million, and RMB 920 million in 2018, 2018, and 2020, respectively, with adjusted net losses of RMB 69.552 million, RMB 123 million, and RMB 149 million, respectively. The company reported a net loss of 764 million yuan in the first quarter of 2021, compared to an adjusted net loss of 88.212 million yuan.</p><p><img src=\"https://static.tigerbbs.com/84671b41e90e8ab7fb7df16b5269a9e7\" tg-width=\"550\" tg-height=\"334\" referrerpolicy=\"no-referrer\"></p><p>In terms of cash flow, as of March 31, 2021, Dingdang Express Pharmaceutical's cash and cash equivalents at the end of the year or period were RMB 427 million.</p><p>The prospectus also shows that the company's express drug service supply recorded a total of 141 million, 264 million, and 405 million sales orders from 2018 to 2020, respectively. During the same period, the platform's online doctor consultation service recorded a total of 100,000, 2.2 million, and 4.4 million online consultations, respectively. For the three months ended March 31, 2021, Dingdang Express recorded 129 million sales orders for its express medicine service and 1.3 million online consultations for its online doctor consultation service.</p><p>In terms of equity, Yang Wenlong, founder of Dingdang Health and Dingdang Express Pharmaceutical, holds a total of 53.23% of the shares, CMB International holds a total of 7.28%, TPG Capital holds 6.34%, SoftBank holds a total of 5.96%, and Taikang Life Insurance holds 2.06%.<a href=\"https://laohu8.com/S/601995\">CICC</a>OrbiMed holds 1.97% of the shares, OrbiMed Capital holds 1.27%, and a fund under Haier Group holds 1.03%.</p><p><img src=\"https://static.tigerbbs.com/b90772c12a9057c339d9c403a112fb15\" tg-width=\"550\" tg-height=\"455\" referrerpolicy=\"no-referrer\"></p>","source":"sina_tech","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDingdang Express Pharmaceutical submitted its Hong Kong IPO application, with a compound annual growth rate of 95.2% over the past three years.\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪科技</strong><span class=\"h-time small\">2021-06-23 22:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p>On the evening of June 23, Dingdang Health Technology Group Co., Ltd., the subsidiary of the internet health delivery service platform \"Dingdang Express Medicine\", submitted a listing application to the Hong Kong Stock Exchange, with CICC and CMB International as joint sponsors.</p><p>According to the prospectus, Dingdang Express Pharmaceutical's revenue was RMB 584.6 million, RMB 1.276 billion, and RMB 2.229 billion in 2018, 2018, and 2020, respectively. For the three months ended March 31, 2021, Dingdang Express's revenue was RMB 780 million. The company achieved a compound annual growth rate of 95.2% from 2018 to 2020.</p><p>In terms of revenue structure, Dingdang Express Pharmaceutical's revenue is mainly contributed by pharmaceutical and medical businesses, accounting for more than 95% of both. During the reporting period, revenue from pharmaceutical and medical services was RMB 562 million, RMB 1.251 billion, RMB 2.204 billion and RMB 761 million, respectively, accounting for 96.2%, 98.1%, 98.9% and 97.6%.</p><p>Dingdang Express Pharmaceutical suffered net losses of RMB 103 million, RMB 274 million, and RMB 920 million in 2018, 2018, and 2020, respectively, with adjusted net losses of RMB 69.552 million, RMB 123 million, and RMB 149 million, respectively. The company reported a net loss of 764 million yuan in the first quarter of 2021, compared to an adjusted net loss of 88.212 million yuan.</p><p><img src=\"https://static.tigerbbs.com/84671b41e90e8ab7fb7df16b5269a9e7\" tg-width=\"550\" tg-height=\"334\" referrerpolicy=\"no-referrer\"></p><p>In terms of cash flow, as of March 31, 2021, Dingdang Express Pharmaceutical's cash and cash equivalents at the end of the year or period were RMB 427 million.</p><p>The prospectus also shows that the company's express drug service supply recorded a total of 141 million, 264 million, and 405 million sales orders from 2018 to 2020, respectively. During the same period, the platform's online doctor consultation service recorded a total of 100,000, 2.2 million, and 4.4 million online consultations, respectively. For the three months ended March 31, 2021, Dingdang Express recorded 129 million sales orders for its express medicine service and 1.3 million online consultations for its online doctor consultation service.</p><p>In terms of equity, Yang Wenlong, founder of Dingdang Health and Dingdang Express Pharmaceutical, holds a total of 53.23% of the shares, CMB International holds a total of 7.28%, TPG Capital holds 6.34%, SoftBank holds a total of 5.96%, and Taikang Life Insurance holds 2.06%.<a href=\"https://laohu8.com/S/601995\">CICC</a>OrbiMed holds 1.97% of the shares, OrbiMed Capital holds 1.27%, and a fund under Haier Group holds 1.03%.</p><p><img src=\"https://static.tigerbbs.com/b90772c12a9057c339d9c403a112fb15\" tg-width=\"550\" tg-height=\"455\" referrerpolicy=\"no-referrer\"></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://finance.sina.com.cn/tech/2021-06-23/doc-ikqciyzk1422330.shtml\">新浪科技</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4e0b225f7e22da3febd11eab17f77d01","relate_stocks":{"HSI":"恒生指数"},"source_url":"https://finance.sina.com.cn/tech/2021-06-23/doc-ikqciyzk1422330.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158050536","content_text":"6月23日晚间消息，互联网健康到家服务平台“叮当快药”所属公司叮当健康科技集团有限公司向港交所递交上市申请，中金与招银国际为联席保荐人。\n招股书显示，叮当快药2018年-2020年的收入分别为5.846亿元，12.76亿元，22.29亿。截至2021年3月31日止三个月，叮当快药收入为7.80亿元。该公司2018年至2020年复合增长率为95.2%。\n按收入结构来看，叮当快药的收入主要由药品及医疗业务贡献，占比均超过95%。报告期内，药品及医疗业务收入分别为5.62亿元、12.51亿元、22.04亿元与7.61亿元，占比分别为96.2%、98.1%、98.9%与97.6%。\n叮当快药2018年-2020年净亏损分别为达1.03亿元，2.74亿元，9.20亿元，经调整后的净亏损分别为6955.2万元、1.23亿元、1.49亿元。该公司2021年第一季度净亏损为7.64亿元，经调整净亏损为8821.2万元。\n\n在现金流方面，截止2021年3月31日，叮当快药的年或期末现金及现金等价物为4.27亿元。\n招股书还显示，该公司快药服务供应2018年至2020年，分别录得合共1.41亿笔、2.64亿笔、4.05亿笔销售订单，同期的平台在线医生诊疗服务分别录得共10万、220万、440万次在线咨询。截至2021年3月31日止三个月，叮当快药的快药服务供应录得1.29亿笔销售订单，平台在线医生诊疗服务录得130万次在线咨询。\n股权方面来看，叮当健康、叮当快药创始人杨文龙合计持有53.23%股权，招银国际合计持股7.28%，TPG Capital持股6.34%，软银合计持股5.96%，泰康人寿保险持股2.06%，中金公司持股1.97%，OrbiMed奥博资本持股1.27%，海尔集团旗下基金持股1.03%。","news_type":1,"symbols_score_info":{"HSI":0.9}},"isVote":1,"tweetType":1,"viewCount":4696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}